# Apnimed

> Apnimed is a late-stage clinical-stage pharmaceutical company headquartered in Cambridge,
> Massachusetts, founded in 2017 to develop novel oral drug therapies for sleep-related
> breathing disorders. Its lead candidate AD109 (Oxnimbi) is a fixed-dose combination of an
> anti-muscarinic and a selective norepinephrine reuptake inhibitor that improves upper-airway
> muscle activity, aimed at an underlying neuromuscular cause of obstructive sleep apnea (OSA)
> rather than mechanical management. Apnimed partners with Shionogi through the
> Shionogi-Apnimed Sleep Science (SASS) joint venture, and its New Drug Application for AD109
> was accepted by the FDA in 2026.

## Status

Apnimed publishes **no public API**, no developer portal, no documentation site and no
machine-readable contract. As of 2026-08-06, probes for `/openapi.json`, `/swagger.json`,
`/api-docs`, `/docs`, `/graphql`, `/llms.txt`, `/.well-known/security.txt`,
`/.well-known/agent-card.json`, `/.well-known/agent.json`, `/.well-known/api-catalog`,
`/.well-known/openid-configuration`, `/.well-known/oauth-authorization-server` and
`/.well-known/ai-plugin.json` all returned 404 on `apnimed.com`, and `api.apnimed.com`,
`docs.apnimed.com` and `developer.apnimed.com` do not resolve in DNS. The investor-relations
host `ir.apnimed.com` is a hosted IR site and returned 404/403 for the same probes. This file
is generated by API Evangelist from the catalog profile, not published by Apnimed.

## Company

- [Apnimed](https://apnimed.com/): Company website.
- [About](https://apnimed.com/about/): Who we are and the company's focus.
- [Our Focus](https://apnimed.com/our-focus/): Sleep-related breathing disease.
- [Leadership](https://apnimed.com/leadership/): Executive team.
- [Careers](https://apnimed.com/careers/): Open roles.
- [Contact Us](https://apnimed.com/contact-us/): Contact form.

## Science and pipeline

- [Product Development Program](https://apnimed.com/product-development-program/): The pipeline.
- [AD109](https://apnimed.com/ad109/): The lead oral candidate for obstructive sleep apnea.
- [Obstructive Sleep Apnea](https://apnimed.com/obstructive-sleep-apnea/): Disease background.
- [Clinical Trials](https://apnimed.com/clinical-trials/): Trial program.
- [Publications](https://apnimed.com/publications/): Scientific publications.
- [OSA Community Stories](https://apnimed.com/osa-community-stories/): Patient stories.

## News and investors

- [News](https://apnimed.com/news/): Company announcements and press releases.
- [RSS feed](https://apnimed.com/feed/): WordPress feed.
- [Investor Relations](https://ir.apnimed.com/): Public-company investor site.
- [Apnimed on Forge Global](https://forgeglobal.com/apnimed_stock/): Secondary-market listing.
- [Apnimed on LinkedIn](https://www.linkedin.com/company/apnimed): Company page.

## Legal

- [Terms and Conditions](https://apnimed.com/terms-and-conditions/)
- [Privacy Policy](https://apnimed.com/privacy-policy/)

## API Evangelist

- [APIs.json profile](https://raw.githubusercontent.com/api-evangelist/apnimed/refs/heads/main/apis.yml)
- [Domain security probe](https://raw.githubusercontent.com/api-evangelist/apnimed/refs/heads/main/security/apnimed-domain-security.yml)